DermatologyNews.net

Dermatology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Onco News

Search results for "Cosentyx"

The phase IIIb CLEAR study for Secukinumab ( Cosentyx ) has demonstrated superiority to Ustekinumab ( Stelara ) and met its primary endpoint of achieving PASI 90, which represents clear or almost clea ...


New data demonstrating that Cosentyx ( Secukinumab ) provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable sa ...


Nail psoriasis is associated with functional impairment, pain and reduced quality of life. The aim of a study was to demonstrate the superiority of Secukinumab ( Cosentyx ) versus placebo in cleari ...


ECLIPSE trial has demonstrated that Guselkumab ( Tremfya ) was superior to Secukinumab ( Cosentyx ) in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at wee ...